Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Mori

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Circulation. Heart Failure|January 7, 2014
Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammationJun Mori, Vaibhav B Patel, Osama Abo Alrob, et al.
The Journal of Clinical Endocrinology and Metabolism|July 5, 2023
Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GHBradley S Miller, Joanne C Blair, Michael Højby Rasmussen, et al.
Blood|February 16, 2010
CLEC-2 activates Syk through dimerizationCraig E Hughes, Alice Y Pollitt, Jun Mori, et al.
Plos One|March 14, 2015
Effect of fatty acids on human bone marrow mesenchymal stem cell energy metabolism and survivalNatasha Fillmore, Alda Huqi, Jagdip S Jaswal, et al.
The Journal of Clinical Endocrinology and Metabolism|November 27, 2018
Pubertal Development and Pregnancy Outcomes in 46,XX Patients With Nonclassic Lipoid Congenital Adrenal HyperplasiaNaomi Hatabu, Naoko Amano, Jun Mori, et al.
Endocrine Journal|November 12, 2025
Diagnostic criteria for acquired hypothalamic obesity - international expert guidance documentHermann L Müller, Tomohiro Tanaka, Tomonobu Hasegawa, et al.
Circulation. Heart Failure|June 19, 2012
Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fractionJun Mori, Ratnadeep Basu, Brent A McLean, et al.
The Journal of Clinical Endocrinology and Metabolism|March 4, 2023
Response to Letter to the Editor From Chatelain et al: "Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial"Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, et al.
European Journal of Endocrinology|May 22, 2025
Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, et al.
The Journal of Clinical Endocrinology and Metabolism|September 5, 2022
Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 TrialBradley S Miller, Joanne C Blair, Michael Højby Rasmussen, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Circulation. Heart Failure|January 7, 2014
Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammationJun Mori, Vaibhav B Patel, Osama Abo Alrob, et al.
The Journal of Clinical Endocrinology and Metabolism|July 5, 2023
Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GHBradley S Miller, Joanne C Blair, Michael Højby Rasmussen, et al.
Blood|February 16, 2010
CLEC-2 activates Syk through dimerizationCraig E Hughes, Alice Y Pollitt, Jun Mori, et al.
Plos One|March 14, 2015
Effect of fatty acids on human bone marrow mesenchymal stem cell energy metabolism and survivalNatasha Fillmore, Alda Huqi, Jagdip S Jaswal, et al.
The Journal of Clinical Endocrinology and Metabolism|November 27, 2018
Pubertal Development and Pregnancy Outcomes in 46,XX Patients With Nonclassic Lipoid Congenital Adrenal HyperplasiaNaomi Hatabu, Naoko Amano, Jun Mori, et al.
Endocrine Journal|November 12, 2025
Diagnostic criteria for acquired hypothalamic obesity - international expert guidance documentHermann L Müller, Tomohiro Tanaka, Tomonobu Hasegawa, et al.
Circulation. Heart Failure|June 19, 2012
Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fractionJun Mori, Ratnadeep Basu, Brent A McLean, et al.
The Journal of Clinical Endocrinology and Metabolism|March 4, 2023
Response to Letter to the Editor From Chatelain et al: "Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial"Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, et al.
European Journal of Endocrinology|May 22, 2025
Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, et al.
The Journal of Clinical Endocrinology and Metabolism|September 5, 2022
Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 TrialBradley S Miller, Joanne C Blair, Michael Højby Rasmussen, et al.
Pageof 12